Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics Receive NICE Recommendation of Kapruvia (difelikefalin) for CKD-Associated Pruritus
Shots:
- The NICE has recommended Kapruvia for treating patients with mod. to sev. CKD-associated pruritus in adult patients on haemodialysis in England, Wales & Northern Ireland
- The recommendation was based on the results from the P-III trials (KALM-1 & 2) as well as supportive data from an additional 32 clinical studies evaluating Kapruvia
- Kapruvia (difelikefalin), the first MHRA-approved treatment for the same indication while the P-III program is ongoing for pruritus in patients with notalgia paresthetica. Additionally, Cara is developing an oral formulation of difelikefalin & has initiated a P-II/III difelikefalin program to treat mod. to sev. pruritus in patients with notalgia paresthetica
Ref: Globeneswire | Image: Cara Therapeutics
Related News:- Vifor & Cara’s Kapruvia (difelikefalin) Receive EC’s Approval for the Treatment of Pruritus in Hemodialysis Patients
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
